Related references
Note: Only part of the references are listed.Contribution of N-Glucuronidation to Efavirenz Elimination In Vivo in the Basal and Rifampin-Induced Metabolism of Efavirenz
Doo-Yeoun Cho et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
E. Gebeyehu et al.
PHARMACOGENOMICS JOURNAL (2011)
Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites
S. K. Bae et al.
XENOBIOTICA (2011)
No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment
Juergen Burhenne et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation
Evan T. Ogburn et al.
DRUG METABOLISM AND DISPOSITION (2010)
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
Laure Elens et al.
PHARMACOGENOMICS (2010)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine
Min Zhu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients
Salvador E. Cabrera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
M. Arab-Alameddine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Anne-Sophie Belanger et al.
DRUG METABOLISM AND DISPOSITION (2009)
Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression
C. J. Smith et al.
HIV MEDICINE (2009)
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
UGT2B7 promoter variant-840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease
Deepika S. Darbari et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Efavirenz - Still first-line king?
Brookie M. Best et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects
Sarah M. Robertson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation
Akiko Nakamura et al.
PHARMACOGENETICS AND GENOMICS (2008)
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
Christopher Nyakutira et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Zeruesenay Desta et al.
PHARMACOGENOMICS (2007)
Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay
Manuela Ehrhardt et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers
E. Levesque et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers
Stephanie R. Faucette et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Metabolism of efavirenz and 8-hydroxyefavirenz by P4502B6 leads to inactivation by two distinct mechanisms
Namandje N. Bumpus et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism
D Burger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
LM Almond et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Metabolism-based drug-drug interactions: What determines individual variability in cytochrome P450 induction?
C Tang et al.
DRUG METABOLISM AND DISPOSITION (2005)
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors
F Maggiolo et al.
CLINICAL INFECTIOUS DISEASES (2005)
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy
RC Brundage et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes:: Specificity and influence of the UGT2B7*2 polymorphism
MH Court et al.
DRUG METABOLISM AND DISPOSITION (2003)
Virological rebound after suppression on highly active antiretroviral therapy
A Mocroft et al.
AIDS (2003)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS clinical trial group study 398
M Pfister et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
C Csajka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients
M Holthe et al.
PHARMACOGENOMICS JOURNAL (2003)
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans
S Mouly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe -: Results from the EuroSIDA Study
R Paredes et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
